AB216261

Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus)

Name: Recombinant Mouse PD-L1 protein (Fc Chimera) (Biotin) (ab216261) | Abcam
Brand: Abcam Limited
SKU: AB216261
Price: 245000 JPY
Availability: InStock

Be the first to review this product! Submit a review

(2 Publications)

Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus) is a Mouse Fragment protein, in the 18 to 238 aa range, expressed in HEK 293 cells, with >90%, suitable for SDS-PAGE.

別名を表示する

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

2 Images

SDS-PAGE - Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus) (AB216261)

SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus) (AB216261)

4-20% SDS-PAGE analysis of 3 μg ab216261.

This protein runs at an apparent higher molecular weight due to glycosylation.

Size Exclusion Chromatography - Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus) (AB216261)

Size Exclusion Chromatography

Supplier Data

Size Exclusion Chromatography - Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus) (AB216261)

Gel filtration curve of ab216261.

Key facts

精製度

>90% SDS-PAGE

発現系

HEK 293 cells

アプリケーション

SDS-PAGE

applications

生物活性

標識

Biotin

励起波長/蛍光波長

アクセッション番号

Q9EP73

アニマルフリー

キャリアフリー

種

Mouse

バッファー組成

pH: 7.4 Constituents: 79% Phosphate Buffer, 20% Glycerol (glycerin, glycerine), 0.64% Sodium chloride, 0.02% Potassium chloride

storage-buffer

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

style

left-column

style

left-column

配列情報

[{"sequence":"AFTITAPKDLYVVEYGSNVTMECRFPVERELDLLALVVYWEKEDEQVIQFVAGEEDLKPQHSNFRGRASLPKDQLLKGNAALQITDVKLQDAGVYCCIISYGGADYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNATANDVFYCTFWRSQPGQNHTAELIIPELPATHPPQNRT","proteinLength":"Fragment","predictedMolecularWeight":"54 kDa","actualMolecularWeight":null,"aminoAcidEnd":238,"aminoAcidStart":18,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q9EP73","tags":[{"tag":"Fc","terminus":"C-Terminus"},{"tag":"Avi","terminus":"C-Terminus"}]}]

style

left-column

出荷温度及び保存条件

出荷温度

Blue Ice

短期保存温度

-80°C

長期保存温度

-80°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

False

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.

Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

style

left-column

製品の性状

製品の状態

Liquid

補足情報

>90% purity as measured by gel filtration.

style

left-column

一般的な情報

機能

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).

配列の類似性

Belongs to the immunoglobulin superfamily. BTN/MOG family.

翻訳後修飾

Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8; leading to degradation. Deubiquitinated by USP22; leading to stabilization.

細胞内局在性

Early endosome membrane

style

left-column

製品プロトコール

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

See full target information Cd274

style

left-column

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 12:670646 PubMed33936116

2021

PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Fanqi Kong,Kaiqiang Sun,Jian Zhu,Fudong Li,Feng Lin,Xiaofei Sun,Xi Luo,Changzhen Ren,Lantao Lu,ShuJie Zhao,Jingchuan Sun,Yuan Wang,Jiangang Shi

JCI insight 5: PubMed32960817

2020

Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.

Applications

Unspecified application

Species

Unspecified reactive species

Ben-Long Liu,Qi-Lai Cao,Xin Zhao,Hui-Zhu Liu,Yu-Qiu Zhang

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Recombinant Mouse PD-L1 protein (Biotin) (Fc tag C-Terminus + Avi tag C-Terminus)